Depletion of immune elements before adoptive cell transfer (ACT) can dramatically improve the antitumor efficacy of transferred CD8+ T cells, but the specific mechanisms that contribute to this enhanced immunity remain poorly defined. Elimination of CD4+CD25+ regulatory T (T reg) cells has been proposed as a key mechanism by which lymphodepletion augments ACT-based immunotherapy. We found that even in the genetic absence of T reg cells, a nonmyeloablative regimen substantially augmented CD8+ T cell reactivity to self-tissue and tumor. Surprisingly, enhanced antitumor efficacy and autoimmunity was caused by increased function rather than increased numbers of tumor-reactive T cells, as would be expected by homeostatic mechanisms. The γC cytokines IL-7 and IL-15 were required for augmenting T cell functionality and antitumor activity. Removal of γC cytokine–responsive endogenous cells using antibody or genetic means resulted in the enhanced antitumor responses similar to those seen after nonmyeloablative conditioning. These data indicate that lymphodepletion removes endogenous cellular elements that act as sinks for cytokines that are capable of augmenting the activity of self/tumor-reactive CD8+ T cells. Thus, the restricted availability of homeostatic cytokines can be a contributing factor to peripheral tolerance, as well as a limiting resource for the effectiveness of tumor-specific T cells.
Skip Nav Destination
Article navigation
3 October 2005
Brief Definitive Report|
October 03 2005
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells
Luca Gattinoni,
Luca Gattinoni
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Search for other works by this author on:
Steven E. Finkelstein,
Steven E. Finkelstein
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Search for other works by this author on:
Christopher A. Klebanoff,
Christopher A. Klebanoff
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
2Howard Hughes Medical Institute, NIH Research Scholars Program, Bethesda, MD 20814
Search for other works by this author on:
Paul A. Antony,
Paul A. Antony
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Search for other works by this author on:
Douglas C. Palmer,
Douglas C. Palmer
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Search for other works by this author on:
Paul J. Spiess,
Paul J. Spiess
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Search for other works by this author on:
Leroy N. Hwang,
Leroy N. Hwang
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Search for other works by this author on:
Zhiya Yu,
Zhiya Yu
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Search for other works by this author on:
Claudia Wrzesinski,
Claudia Wrzesinski
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Search for other works by this author on:
David M. Heimann,
David M. Heimann
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Search for other works by this author on:
Charles D. Surh,
Charles D. Surh
3Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037
Search for other works by this author on:
Steven A. Rosenberg,
Steven A. Rosenberg
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Search for other works by this author on:
Nicholas P. Restifo
Nicholas P. Restifo
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Search for other works by this author on:
Luca Gattinoni
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Steven E. Finkelstein
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Christopher A. Klebanoff
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
2Howard Hughes Medical Institute, NIH Research Scholars Program, Bethesda, MD 20814
Paul A. Antony
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Douglas C. Palmer
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Paul J. Spiess
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Leroy N. Hwang
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Zhiya Yu
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Claudia Wrzesinski
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
David M. Heimann
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Charles D. Surh
3Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037
Steven A. Rosenberg
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
Nicholas P. Restifo
1Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892
CORRESPONDENCE Nicholas P. Restifo: [email protected]
L. Gattinoni, S.E. Finkelstein, and C.A. Klebanoff contributed equally to this work.
Received:
April 12 2005
Accepted:
August 16 2005
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2005
J Exp Med (2005) 202 (7): 907–912.
Article history
Received:
April 12 2005
Accepted:
August 16 2005
Citation
Luca Gattinoni, Steven E. Finkelstein, Christopher A. Klebanoff, Paul A. Antony, Douglas C. Palmer, Paul J. Spiess, Leroy N. Hwang, Zhiya Yu, Claudia Wrzesinski, David M. Heimann, Charles D. Surh, Steven A. Rosenberg, Nicholas P. Restifo; Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells . J Exp Med 3 October 2005; 202 (7): 907–912. doi: https://doi.org/10.1084/jem.20050732
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement